SunCar Technology Group Inc. Schedules Full-Year 2024 Earnings Conference Call
NEW YORK--(BUSINESS WIRE)--SunCar Technology Group Inc. (the "Company" or "SunCar") (NASDAQ: SDA), an innovative leader in cloud-based, software-focused B2B auto eInsurance and auto services in China, will release its financial results for the full year 2024 on Monday, April 28 after the market closes.
SunCar will host a conference call the following day on Tuesday, April 29 th at 8:00 AM ET (5:00 AM PT) with the investment community to discuss the Company's financial results and provide a business update.
Investors may submit written questions by Monday, April 28 via e-mail to: IR@suncartech.com
To access the call by phone, please dial 1-877-407-0752 (international callers please dial 1-201-389-0912) approximately 10 minutes prior to the start of the call. An audio webcast of the conference call will be available online at https://viavid.webcasts.com/starthere.jsp?ei=1716706&tp_key=51381ecbeb.
A webcast replay will also be available for a limited time at the following link: https://viavid.webcasts.com/starthere.jsp?ei=1716706&tp_key=51381ecbeb.
The conference call will be open to all interested parties. In accordance with Regulation FD (Fair Disclosure), all investors will have equal access to the information shared during this call.
During the conference call, management may discuss certain non-GAAP financial measures. In accordance with Regulation G, reconciliations of any non-GAAP financial measures to their most directly comparable GAAP measures will be available in the earnings release or accompanying materials that will be posted on the Company's investor relations website prior to the conference call.
About SunCar Technology Group Inc.
Founded in 2007, SunCar is transforming the customer journey for auto eInsurance and auto services in China, the largest passenger vehicle market in the world. SunCar develops and operates cloud-based platforms that seamlessly connect drivers with a wide range of eInsurance coverage options and auto services through a nationwide network of sales partners. As a result, SunCar has established itself as the leader in China in the B2B auto eInsurance and auto services market for electric vehicles. The Company's intelligent cloud platform empowers its enterprise customers to access, manage, and optimize their auto services offerings as their end customers gain access to hundreds of services from tens of thousands of independent providers from a single application. For more information, please visit: https://suncartech.com.
Forward-Looking Statements
This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. For a detailed discussion of these risks, please refer to the Company's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
20 minutes ago
- Business Wire
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. ( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the following link: The event and accompanying slides can also be accessed by visiting the investor relations section of the company's website at An archived webcast will be available on the company's website following the event. The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge. In addition to safety and tolerability, the study assessed morphologic and inflammatory endpoints along with gluten challenge (GC) induced symptoms. FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (change from baseline). The mean VCIEL change from baseline was -1.849 for placebo subjects compared to 0.079 for FB102 treated subjects (p=0.0099). The change in the density of CD3-positive T cells, or IELs, from baseline was an increase of 13.3 for placebo subjects compared to a decline of 1.5 for FB102 treated subjects (p=0.0035). Baseline IEL density was 25.6 for the placebo subjects and 23.5 for the FB102 treated subjects. The mean change in the Vh:Cd ratio from baseline was -0.173 (0.21) for placebo subjects compared to -0.046 (0.09), a 73% improvement for FB102 treated subjects compared to placebo. Gluten challenge induced GI symptoms (nausea, vomiting, diarrhea, abdominal pain and abdominal bloating) reported during the 16 day gluten challenge from patient diaries/AE collection demonstrated a 42% benefit for FB102 treated subject (4.0 events per subject) compared to placebo (6.9 events per subject). There were no dropouts in the study. Treatment emergent adverse events (TEAE) were primarily mild (grade 1) with no grade 3 or higher SAEs reported in the FB102 arm. 'We want to congratulate all of the investigators and researchers that supported this study. I also want to acknowledge the incredible dedication and hard work of the Forte team. Celiac disease is debilitating for many patients with even trace exposure to gluten. FB102 has taken a big step forward towards addressing this very large unmet need with the results from this study. The Phase 2 celiac disease study is initiating with a topline readout expected in 2026.' said Paul Wagner, Ph.D. CEO and Chairperson of Forte Biosciences. 'These results are also very encouraging given the biology of the additional FB102 indications including vitiligo, alopecia areata and type 1 diabetes. We also look forward to reading out the topline results of the FB102 vitiligo study in the first half of 2026.' About Forte Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. Forward-Looking Statements Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential' or 'continue' or the negatives of these terms or other similar expressions. These statements are based on the Forte's current beliefs and expectations. Forward-looking statements include statements regarding Forte's beliefs, goals, intentions and expectations regarding its product candidate, FB102 and the therapeutic and commercial market potential of FB102, the expected timeline for the Phase 2 celiac study and related readout, and the expected timing of topline results for the FB102 vitiligo study. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks related to Forte's ability to obtain sufficient additional capital to continue to advance Forte's product candidate, FB102; uncertainties associated with the clinical development and regulatory approval of Forte's product candidate, FB102, including potential delays in the commencement, enrollment and completion of clinical trials; the risk that results from preclinical and the Phase 1b trials may not be predictive of future results from clinical trials; risks associated with the failure to realize any value from FB102 in light of inherent risks, expense and difficulties involved in successfully bringing product candidates to market; and additional risks, uncertainties, and other information affecting Forte's business and operating results is contained in Forte's Quarterly Report on Forms 10-Q filed on May 15, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Source: Forte Biosciences, Inc.
Yahoo
30 minutes ago
- Yahoo
Is Fox Stock Outperforming the Nasdaq?
New York-based Fox Corporation (FOX) operates as a news, sports, and entertainment company in the United States. With a market cap of $22.8 billion, the company operates through Cable Network Programming, Television, Credible, and The FOX Studio Lot segments. Companies worth $10 billion or more are generally described as "large-cap stocks." FOX fits right into that category, with its market cap exceeding the threshold, reflecting its substantial size and influence in the competitive industry of entertainment. FOX benefits from being one of the largest cable TV networks in the United States, offering a wide range of content. Robotaxis, Powell and Other Key Things to Watch this Week Make Over a 2.4% One-Month Yield Shorting Nvidia Out-of-the-Money Puts Is Quantum Computing (QUBT) Stock a Buy on This Bold Technological Breakthrough? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! FOX currently trades 7.8% below its all-time high of $55 recorded on Mar. 3. FOX's stock has gained 2.7% over the past three months, notably underperforming the Nasdaq Composite's ($NASX) 9.9% uptick during the same time frame. In the long term, FOX stock has surged 10.9% on a YTD basis, outperforming the Nasdaq's marginal increase. Moreover, shares of FOX soared 59% over the past 52 weeks, also outperforming Nasdaq's 9.7% returns over the same period. To confirm its bullish trend, FOX has been trading above its 200-day moving average for the past year and also above its 50-day moving average since mid-May. FOX shares rose 4.3% following the release of its better-than-expected Q3 earnings on May 12. The company's total revenues increased 26.8% year-over-year to $4.4 billion, mainly driven by a robust growth in the revenue of its affiliate fee, advertising, and other components, and also surpassed the Street's estimates. Its adjusted EBITDA, however, decreased 3.9% to $856 million, caused by an increase in expenses due to higher sports programming rights amortization and production costs driven by the broadcast of Super Bowl LIX and higher digital content and marketing costs. FOX's adjusted earnings increased marginally year-over-year to $1.09 and surpassed the consensus estimates by 14.6%. Its rival, News Corporation (NWSA), has gained 2.9% in 2025 and 5.4% over the past year, underperforming FOX. Among the 13 analysts covering the FOX stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $54.92 suggests an 8.2% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Business Wire
33 minutes ago
- Business Wire
NPK Announces New $150 Million Revolving Credit Facility
THE WOODLANDS, Texas--(BUSINESS WIRE)--NPK International Inc. (NYSE: NPKI) ('NPK' or the 'Company') today announced that it has entered into a new credit agreement ('Agreement') effective June 20, 2025, which includes a $150 million revolving loan facility, replacing the Company's previous asset-based revolving credit facility. The Agreement has a term of five years and also includes an accordion feature, allowing for the expansion of the revolving loan facility up to $250 million. Under the terms of the Agreement, revolving loans bear interest at either Term SOFR plus 175 to 225 basis points or the Base Rate plus 75 to 125 basis points, with the applicable margin determined based on the Company's consolidated leverage ratio, as calculated in accordance with the Agreement. The bank group participating in the facility includes Bank of America, N.A., Amegy Bank, Regions Bank, First Horizon Bank, Texas Capital Bank and Woodforest National Bank. Gregg Piontek, NPK's Senior Vice President and Chief Financial Officer, stated, "We are very pleased to have the support of our bank group, including our long-term partners, as well as new partnerships established through this Agreement. The new facility provides expanded liquidity and improved flexibility, better enabling us to execute on our long-term growth strategy and capital allocation priorities, consistent with our focus on driving long-term value creation for our shareholders." For further information regarding the Agreement, please refer to the Company's Current Report on Form 8-K, to be filed with the Securities and Exchange Commission on or before June 26, 2025. ABOUT NPK INTERNATIONAL NPK International Inc. is a worksite access solutions company that manufactures, sells, and rents industry-leading sustainable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The Company delivers superior quality and reliability across critical infrastructure markets, including electrical transmission & distribution, oil and gas exploration, pipeline, renewable energy, petrochemical, construction, and other industries. For more information, visit our website at FORWARD-LOOKING STATEMENTS This news release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical facts are forward-looking statements. Words such as 'will,' 'may,' 'could,' 'would,' 'should,' 'anticipates,' 'believes,' 'estimates,' 'expects,' 'plans,' 'intends,' 'guidance,' and similar expressions are intended to identify these forward-looking statements but are not the exclusive means of identifying them. These statements are not guarantees that our expectations will prove to be correct and involve a number of risks, uncertainties, and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents filed with the Securities and Exchange Commission by NPK, particularly its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q, as well as others, could cause actual plans or results to differ materially from those expressed in, or implied by, these statements. These risk factors include, but are not limited to, risks related to our sale of the Fluids Systems business; our ability to generate organic growth; economic and market conditions that may impact our customers' future spending; the effective management of our fleet, including our ability to properly manufacture, safeguard, and maintain our fleet; international operations; operating hazards present in our and our customers' industries and substantial liability claims; our contracts that can be terminated or downsized by our customers without penalty; our product offering and market expansion; our ability to attract, retain, and develop qualified leaders, key employees, and skilled personnel; expanding our services in the utilities sector, which may require unionized labor; the price and availability of raw materials; inflation; capital investments and business acquisitions; market competition; technological developments and intellectual property; severe weather, natural disasters, and seasonality; public health crises, epidemics, and pandemics; our cost and continued availability of borrowed funds, including noncompliance with debt covenants; environmental laws and regulations; legal compliance; the inherent limitations of insurance coverage; income taxes; cybersecurity incidents or business system disruptions; activist stockholders that may attempt to effect changes at our Company or acquire control over our Company; share repurchases; and our amended and restated bylaws, which could limit our stockholders' ability to obtain what such stockholders believe to be a favorable judicial forum for disputes with us or our directors, officers or other employees. We assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by securities laws. NPK's filings with the Securities and Exchange Commission can be obtained at no charge at as well as through our website at
